
Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 6 chart positions in 6 markets.
By chart position
- 🇨🇦CA · Medicine#1465K to 30K
- 🇳🇱NL · Medicine#5030K to 100K
- 🇯🇵JP · Medicine#7510K to 30K
- 🇭🇺HU · Medicine#883K to 10K
- 🇨🇴CO · Medicine#159500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
15K to 53K🎙 Daily cadence·126 episodes·Last published 2d ago - Monthly Reach
Unique listeners across all episodes (30 days)
49K to 176K🇳🇱57%🇨🇦17%🇯🇵17%+3 more - Active Followers
Loyal subscribers who consistently listen
20K to 70K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 19 epsHosts
Recent guests
Recent episodes
Author Interviews: cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant Gliomas
Jul 6, 2026
Unknown duration
A Conversation on Career Journeys with SNO's Young Investigator Committee Chairs
Jun 26, 2026
Unknown duration
Neuro-onc Narratives: Two Insiders, One Diagnosis: A Neurosurgeon and Healthcare Leader on Living with GBM
Jun 19, 2026
Unknown duration
Ivosidenib in predominantly recurrent IDH1-mutant glioma: A single-institution experience
Jun 15, 2026
Unknown duration
Author Interview: Prospective biopsy-controlled validation of an AI model for predicting glioblastoma infiltration: Results from the SupraGlio trial
Jun 1, 2026
29m 19s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/6/26 | ![]() Author Interviews: cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant Gliomas | · Podcast Host and Interviewee: o Host: Franziska Ippen o Interviewee: Daniel Brat Podcast Description: Dr. Franziska Ippen interviews Dr. Daniel Brat on his recent Neuro-oncology article entitled "cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant Gliomas". | — | ||||||
| 6/26/26 | ![]() A Conversation on Career Journeys with SNO's Young Investigator Committee Chairs | Host: Evan Noch; Interviewees: Jasia Mahdi, Jacob Young, Alireza Mansouri Evan Noch interviews the Co-chairs of SNO's Young Investigator Committee about their advice on career journeys for early-career trainees | — | ||||||
| 6/19/26 | ![]() Neuro-onc Narratives: Two Insiders, One Diagnosis: A Neurosurgeon and Healthcare Leader on Living with GBM | Host: Akanksha Sharma, MD Interviewee: Shannon Thomas, RN, MSN Podcast Description: Dr Sharma has a candid, reflective conversation with Shannon Thomas, CEO of Eden Medical Center in Castro Valley, CA, and the wife of Dr. Ronnie Mimran – a beloved physician and highly skilled neurosurgeon known for his patient care and bedside manner. Dr Mimran is living with glioblastoma; he was diagnosed almost 3 years ago. We discuss her perspective as not only a caregiver but a nurse and healthcare executive, and what they have learned on this journey. | — | ||||||
| 6/15/26 | ![]() Ivosidenib in predominantly recurrent IDH1-mutant glioma: A single-institution experience | Podcast Host and Interviewee: Host: John Fortunato Interviewee: Sofia Rael, Ugur Sener Podcast Description: Dr. John Fortunato interviews Dr. Sofia Rael and Dr. Ugur Sener on their recent manuscript, titled "Ivosidenib in predominantly recurrent IDH1-mutant glioma: A single institution experience." | — | ||||||
| 6/1/26 | ![]() Author Interview: Prospective biopsy-controlled validation of an AI model for predicting glioblastoma infiltration: Results from the SupraGlio trial✨ | glioblastomaAI model+3 | Santiago Cepeda | Prospective biopsy-controlled validation of an AI model for predicting glioblastoma infiltration: Results from the SupraGlio trial | — | glioblastomaAI+5 | — | 29m 19s | |
| 5/30/26 | ![]() Neuro-Oncology Nugget: GT-20 Phase 1 Trial — Personalized Neoantigen DNA Vaccine for MGMT Unmethylated Glioblastoma✨ | clinical trialpersonalized medicine+3 | Shahad Abdulsahib | GNOS-PV01UT Health San Antonio+1 | — | GT-20MGMT unmethylated glioblastoma+3 | — | 3m 19s | |
| 5/25/26 | ![]() Author Interview Series SNO Podcast May 2026✨ | neuro-oncologybiomarker-guided therapies+3 | Prof. Dr. Ghazaleh Tabatabai | Hertie Institute for Clinical Brain ResearchUniversity Hospital Tübingen+1 | — | neuro-oncologybiomarkers+3 | — | 16m 23s | |
| 5/18/26 | ![]() Neuro-Oncology Narrative✨ | Neurosurgeryinterview+3 | Sarah MenachoBen Shofty | Neurosurgery | — | Neurosurgeryinterview+3 | — | 34m 26s | |
| 5/15/26 | ![]() Hot Topics: Wellness in Neuro-oncology✨ | wellnessburnout+3 | Nick Gonzalez CastroRaj Mukherjee | SNO Wellness Committee | — | wellnessburnout+3 | — | 24m 37s | |
| 5/11/26 | ![]() Neuro-Oncology Nugget: Phase 1/2 BT008NA Trial — Focused Ultrasound + Temozolomide for High-Grade Glioma✨ | clinical trialfocused ultrasound+3 | — | temozolomideUT Health San Antonio+1 | high-grade glioma | BT008NA trialfocused ultrasound+4 | — | 3m 56s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 5/8/26 | ![]() SNObound: Career description and advice from Dr. Ryan Cecchi in Neuropathology✨ | neuropathologyneuro-oncology+3 | Dr. Ryan Cecchi | — | — | neuropathologyneuro-oncology+5 | — | 19m 35s | |
| 5/4/26 | ![]() CATNON Conclusion: Closure on concurrent chemotherapy in IDHmt Grade 3 Astrocytoma✨ | chemotherapyIDHmt+4 | David Schiff | CATNON Conclusion: Closure on concurrent chemotherapy in IDHmt Grade 3 Astrocytoma | — | chemotherapyIDHmt+5 | — | 27m 33s | |
| 5/1/26 | ![]() Hot Topics: What's next in neuro-oncology✨ | neuro-oncologymedical advancements+3 | Dr. Fabio Iwamoto | Stanford | — | neuro-oncologyDr. Fabio Iwamoto+3 | — | 16m 48s | |
| 4/27/26 | ![]() Neuro-Oncology Nugget: Career Development Outreach from SNO✨ | career developmentneuro-oncology+1 | — | SNO | — | career developmentneuro-oncology+3 | — | 3m 11s | |
| 4/24/26 | ![]() Neuro-onc Narratives: An Interview with Caroline Catlin✨ | brain tumorart therapy+3 | Caroline Catlin | The New York TimesLongreads+3 | — | brain tumorart+5 | — | 38m 06s | |
| 4/20/26 | ![]() Author Interview: "DNA copy number patterns reveal prognostic markers and elucidate mechanisms of evolution in IDH-mutant astrocytoma"✨ | IDH-mutant astrocytomaDNA copy number patterns+4 | Bob Jenkins | DNA copy number patterns reveal prognostic markers and elucidate mechanisms of evolution in IDH-mutant astrocytoma | — | IDH-mutant astrocytomaDNA copy number+4 | — | 35m 16s | |
| 4/17/26 | ![]() Hot Topics: AYA in Neuro-Oncology✨ | adolescent and young adultneuro-oncology+2 | Dr. Mary Jane (MJ) Lim-FatDr. Kee Kiat (Aaron) Yeo | Neuro-Oncology | — | AYAneuro-oncology+4 | — | 31m 43s | |
| 4/13/26 | ![]() Neuro-Oncology Nugget: Bivalent EGFR/IL13Rα2 CAR T Cells for Recurrent Glioblastoma✨ | CAR T cellsglioblastoma+3 | Shahad Abdulsahib | bivalent EGFR/IL13Rα2 CAR T cellsNature Medicine | recurrent glioblastoma | CAR T cellsglioblastoma+5 | — | 2m 29s | |
| 4/10/26 | ![]() SNObound: Career Advice from Dr. Brooke Braman in Radiation Oncology✨ | career adviceradiation oncology+3 | Dr. Brooke Braman | Radiation Oncology | — | radiation oncologycareer advice+3 | — | 23m 04s | |
| 4/6/26 | ![]() Author Interview: Global analysis of clinical trials for children and adolescents with CNS tumors✨ | clinical trialsCNS tumors+3 | Dr. Margit K. MikkelsenDr. Daniel C. Moreira | St. Jude Children's Research HospitalNeuro-Oncology Pediatrics+1 | — | clinical trialsCNS tumors+5 | — | 20m 41s | |
| 3/23/26 | ![]() Neuro-Oncology Nugget: Intracerebroventricular B7-H3 CAR T Cells for DIPG✨ | DIPGCAR T cells+3 | Shahad Abdulsahib | Nature Medicineintracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma | — | DIPGB7-H3+4 | — | 2m 52s | |
| 3/20/26 | ![]() Neuro-onc Narratives: Advocating for patient well-being in neuro-oncology✨ | patient well-beingneuro-oncology+3 | Dr. Ashlee LoughanDr. Sarah Brahn | Neuro-Oncology | — | neuro-oncologypatient advocacy+3 | — | 42m 50s | |
| 3/16/26 | ![]() Author Interview: Visual morbidity, long-term outcome, and prognostic factors in infants and young children with optic pathway low-grade glioma✨ | optic pathway low-grade gliomavisual morbidity+3 | Dr. Stefania PicarielloDr. Enrico Opocher | Visual morbidity, long-term outcome, and prognostic factors in infants and young children with optic pathway low-grade glioma | — | optic pathway gliomavisual morbidity+3 | — | 17m 33s | |
| 3/13/26 | ![]() Hot Topics: Clinician-Patient Relationship in Neuro-Oncology | Dr. Dave Rogawski interviews Dr. Akanksha Sharma on how we can optimize the meaningful, longitudinal relationships that drew many of us to the field. | — | ||||||
| 3/9/26 | ![]() Neuro-Oncology Nugget: Targeted Radiotherapy Using Rhenium-186 Nanoliposomes for Recurrent Glioma | Podcast Host and Interviewee: Shahad Abdulsahib, PhD Candidate, UT Health San Antonio Podcast Description: Shahad Abdulsahib discusses a recent Phase 1 clinical trial on Rhenium-186 nanoliposome therapy for recurrent glioma, published in Nature Communications in March 2025. | — | ||||||
Showing 25 of 144
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Chart Positions
6 placements across 6 markets.
Chart Positions
6 placements across 6 markets.




